STAT Plus: Vertex and U.K. health officials reach an impasse over pricey cystic fibrosis drug

Coverage of a pricey cystic fibrosis drug has Vertex and U.K. health officials locked in a stalemate.

More From BioPortfolio on "STAT Plus: Vertex and U.K. health officials reach an impasse over pricey cystic fibrosis drug"